Apr 11, 2023
Immutep Announces Changes to the Board
Mar 31, 2023
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023
Mar 30, 2023
Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer
Mar 22, 2023
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
Mar 13, 2023
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Feb 06, 2023
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Jan 29, 2023
Immutep Quarterly Activities Report
Jan 03, 2023
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
Dec 22, 2022
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
Dec 07, 2022
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Dec 05, 2022
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
Dec 01, 2022
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
